Trials & Filings

Proteostasis Gets Positive Preclinical Results in COVID-19

PTI-129, a once-daily, oral small molecule demonstrates the potential to reduce viral protein production in host cells.

By: Contract Pharma

Contract Pharma Staff

Proteostasis Therapeutics, Inc., a clinical stage biopharma company developing therapies to treat cystic fibrosis (CF), announced results from in vitro studies evaluating the use of PTI-129 as a treatment for COVID-19. PTI-129 is a preclinical, once-daily, oral small molecule originally designed to treat protein misfolding disorders involving the unfolded protein response (UPR). Upon infection, coronaviruses hijack the host cell endoplasmic reticulum (ER) to quickly produce a larger quantity of...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters